Synthetic Lethality in ERCC1-deficient Non-Small Cell Lung Cancer

被引：0
|
作者：
Postel-Vinay, S. [1 ]
Bajrami, I. [2 ]
Friboulet, L. [1 ]
Jaco, I. [2 ]
Fontebasso, Y. [2 ]
Olaussen, K. A. [1 ]
Soria, J. C. [3 ]
Andre, F. [1 ]
Lord, C. J. [2 ]
Ashworth, A. [2 ]
机构：
[1] Inst Gustave Roussy, INSERM, U981, F-94805 Villejuif, France
[2] Breakthrough Breast Canc Ctr, Inst Canc Res, London, England
[3] Univ Paris 11, Dept Med, Inst Gustave Roussy, Villejuif, France
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)72086-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
288
引用
收藏
页码：88 / 88
页数：1
相关论文
共 50 条
  • [31] The value of research for ERCC1 testing in stage I non-small cell lung cancer (NSCLC).
    Roth, J. A.
    Carlson, J. J.
    Steuten, L.
    Ramsey, S. D.
    Veenstra, D. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Synergistic effects of olaparib combined with ERCC1 on the sensitivity of cisplatin in non-small cell lung cancer
    Xie, Kejie
    Ni, Xiaoyan
    Lv, Shanmei
    Zhou, Guozhong
    He, Honger
    ONCOLOGY LETTERS, 2021, 21 (05)
  • [33] Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients
    Suk, R
    Gurubhagavatula, S
    Park, S
    Zhou, W
    Su, L
    Lynch, TJ
    Wain, JC
    Neuberg, D
    Liu, G
    Christiani, DC
    CLINICAL CANCER RESEARCH, 2005, 11 (04) : 1534 - 1538
  • [34] Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer
    Gao, H.
    Ge, R. C.
    Liu, H. Y.
    Wang, Y.
    Yan, S.
    GENETICS AND MOLECULAR RESEARCH, 2014, 13 (04) : 8997 - 9004
  • [35] Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients
    Ryu, J
    Park, S
    Kwak, S
    Hong, Y
    Kim, J
    Cho, J
    Lee, H
    LUNG CANCER, 2005, 49 : S376 - S376
  • [36] Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes
    Davidson, Kathryn
    Grevitt, Paul
    Contreras-Gerenas, Maria F.
    Bridge, Katherine S.
    Hermida, Miguel
    Shah, Kunal M.
    Mardakheh, Faraz K.
    Stubbs, Mark
    Burke, Rosemary
    Casado, Pedro
    Cutillas, Pedro R.
    Martin, Sarah A.
    Sharp, Tyson, V
    CELL DEATH & DISEASE, 2021, 12 (11)
  • [37] Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes
    Kathryn Davidson
    Paul Grevitt
    Maria F. Contreras-Gerenas
    Katherine S. Bridge
    Miguel Hermida
    Kunal M. Shah
    Faraz K. Mardakheh
    Mark Stubbs
    Rosemary Burke
    Pedro Casado
    Pedro R. Cutillas
    Sarah A. Martin
    Tyson V. Sharp
    Cell Death & Disease, 12
  • [38] Progression of prostate carcinogenesis in ERCC1-deficient prostatic tissue
    Matoka, DJ
    Yao, V
    Bacich, DJ
    JOURNAL OF UROLOGY, 2006, 175 (04): : 264 - 264
  • [39] ERCC1-deficient cells and mice are hypersensitive to lipid peroxidation
    Czerwiriska, Jolanta
    Nowak, Malgorzata
    Wojtczak, Patrycja
    Dziuban-Lech, Dorota
    Ciesla, Jaroslaw M.
    Kolata, Daria
    Gajewska, Beata
    Baranczyk-Kuzma, Anna
    Robinson, Andria R.
    Shane, Hillary L.
    Gregg, Siobhan Q.
    Rigatti, Lora H.
    Yousefzadeh, Matthew J.
    Gurkar, Aditi U.
    McGowan, Sara J.
    Kosicki, Konrad
    Bednarek, Malgorzata
    Zarakowska, Ewelina
    Gackowski, Daniel
    Olinski, Ryszard
    Speina, Elzbieta
    Niedernhofer, Laura J.
    Tudek, Barbara
    FREE RADICAL BIOLOGY AND MEDICINE, 2018, 124 : 79 - 96
  • [40] ERCC6 plays a promoting role in the progression of non-small cell lung cancer
    Luo, Hui
    Xiao, Zhehao
    Huang, Cheng
    Wu, Wei
    Xie, Qingbin
    BIOCHEMISTRY AND CELL BIOLOGY, 2023, 101 (03) : 246 - 258
12345